- Home
- DAC vs GYRE Comparison
DAC vs GYRE Comparison
Compare DAC & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAC
- GYRE
- Stock Information
- Founded
- DAC 1972
- GYRE 2002
- Country
- DAC Greece
- GYRE United States
- Employees
- DAC N/A
- GYRE N/A
- Industry
- DAC Marine Transportation
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- DAC Consumer Discretionary
- GYRE Health Care
- Exchange
- DAC Nasdaq
- GYRE Nasdaq
- Market Cap
- DAC 1.6B
- GYRE 1.3B
- IPO Year
- DAC 2006
- GYRE N/A
- Fundamental
- Price
- DAC $79.84
- GYRE $11.90
- Analyst Decision
- DAC Strong Buy
- GYRE
- Analyst Count
- DAC 1
- GYRE 0
- Target Price
- DAC $105.00
- GYRE N/A
- AVG Volume (30 Days)
- DAC 134.3K
- GYRE 144.2K
- Earning Date
- DAC 02-11-2025
- GYRE 11-13-2024
- Dividend Yield
- DAC 4.07%
- GYRE N/A
- EPS Growth
- DAC 0.27
- GYRE N/A
- EPS
- DAC 28.90
- GYRE N/A
- Revenue
- DAC $1,005,246,000.00
- GYRE $105,033,000.00
- Revenue This Year
- DAC $1.25
- GYRE $25.32
- Revenue Next Year
- DAC $5.60
- GYRE $12.95
- P/E Ratio
- DAC $2.75
- GYRE N/A
- Revenue Growth
- DAC 2.92
- GYRE N/A
- 52 Week Low
- DAC $69.33
- GYRE $8.26
- 52 Week High
- DAC $98.25
- GYRE $30.39
- Technical
- Relative Strength Index (RSI)
- DAC 48.75
- GYRE 52.33
- Support Level
- DAC $75.52
- GYRE $10.39
- Resistance Level
- DAC $79.67
- GYRE $12.59
- Average True Range (ATR)
- DAC 1.82
- GYRE 1.07
- MACD
- DAC 0.01
- GYRE 0.28
- Stochastic Oscillator
- DAC 60.59
- GYRE 68.77
About DAC Danaos Corporation
Danaos Corp is an international owner of containerships. It provides international seaborne transportation services by operating vessels in the containership sector of the shipping industry. The company's customers include, HMM, MSC, Yang Ming, Hapag Lloyd, ZIM, Maersk, COSCO, OOCL, ONE, PIL, Sealead, Niledutch, Samudera, OSC, and Arkas. Geographically, the company operates in Australia-Asia, Europe, and America, with maximum revenue from the Australia-Asia region. It has two reporting segments Container vessels and Drybulk vessels segment. It generates the majority of its revenue from Container vessels.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.